DUBLIN--(BUSINESS WIRE)--The "Global Migraine Market: Industry Analysis & Outlook (2018-2022)" report has been added to ResearchAndMarkets.com's offering.
This report provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, with focus majorly on the U.S. market. The report profiles the key players of the market including Amgen Inc., Eli Lilly and Company, Teva Pharmaceuticals & Alder Biopharmaceuticals.
The global migraine market is expected to grow in future due to increasing female population, rising health expenditure, accelerating economic growth, increasing cigarette consumption, rising prevalence of migraine and unmet needs.
Key trends of this market include development of migraine drugs and growing awareness regarding migraine and its treatments.
However, there are some factors which can hinder the growth of migraine market which includes regulatory challenges, high cost, adverse effects of drugs, lack of proper diagnosis and increased preference of alternative therapies.
Key Topics Covered
2. Global Market Analysis
2.1 Global Migraine Market by Value
2.2 Global Migraine Market Forecast by Value
2.3 Global Migraine Market by Drug Type
2.4 Global Therapeutic Botulinum Toxin Market Forecast by Value
2.5 Global Therapeutic Botulinum Toxin Market by Indication
3. Regional Market
3.1 The U.S.
3.2 The U.S. Migraine Drugs Revenue
3.4 Europe Migraine Drug Revenue
4. Market Dynamics
4.1 Growth Drivers
4.2 Key Trends & Development
5.1 Global Market
6. Company Profiles
6.1 Amgen Inc.
6.2 Eli Lilly and Company
6.3 Teva Pharmaceuticals
6.4 Alder Biopharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/research/s6mmrh/global_migraine?w=4